To date, there are very limited therapies for patients with metastatic castrate resistant prostate cancer. Due to the heterogeneity of prostate cancer no one specific oncogene, mutation, signaling pathways, or risk factor has been described in prostate cancer. Multiple pathways have been described to contribute to both the development as well as progression of prostate cancer. Hsp90 has been shown to be over-expressed in prostate cancer and serves as a hub for multiple signaling pathways that contribute to malignant growth and proliferation, making it an excellent target for the development of inhibitors. In contrast to N-terminal inhibitors that induce the pro-survival heat shock response, C-terminal inhibitors do not, and therefore provide a new paradigm in cancer research. Specifically, we aim to prepare conformationally biased analogues of new Hsp90 C-terminal inhibitors, evaluate them through a series of novel assays in vitro, and then administer select compounds to an orthotopic model of prostate cancer to determine their efficacy. Upon completion of this project, we aim to produce compounds amenable to further evaluation in clinical trials for prostate cancer.

Public Health Relevance

The development of cancer chemotherapeutics that target multiple pathways simultaneously represent an emerging paradigm in medicinal chemistry/drug design. Utilizing the techniques described in this application, inhibitors of the Hsp90-mediated protein folding process will be rationally developed with the aim of producing compounds that effectively block prostate cancer progression and growth and may be suitable for subsequent clinical evaluation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA167079-03
Application #
8627592
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Misra, Raj N
Project Start
2012-04-06
Project End
2017-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
3
Fiscal Year
2014
Total Cost
$302,858
Indirect Cost
$47,383
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Hall, Jessica A; Seedarala, Sahithi; Zhao, Huiping et al. (2016) Novobiocin Analogues That Inhibit the MAPK Pathway. J Med Chem 59:925-33
Liu, Weiya; Vielhauer, George A; Holzbeierlein, Jeffrey M et al. (2015) KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells. Mol Pharmacol 88:121-30
Dunn, Diana M; Woodford, Mark R; Truman, Andrew W et al. (2015) c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Rep 12:1006-18
Ghosh, Suman; Shinogle, Heather E; Garg, Gaurav et al. (2015) Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chem Biol 10:577-90
Zhao, Huiping; Garg, Gaurav; Zhao, Jinbo et al. (2015) Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors. Eur J Med Chem 89:442-66
Kusuma, Bhaskar Reddy; Khandelwal, Anuj; Gu, Wen et al. (2014) Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorg Med Chem 22:1441-9
Moroni, Elisabetta; Zhao, Huiping; Blagg, Brian S J et al. (2014) Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model 54:195-208
Zhao, Jinbo; Zhao, Huiping; Hall, Jessica A et al. (2014) Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm 5:1317-1323
Diaz, Francisco J; McDonald, Peter R; Roy, Anuradha et al. (2013) Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays. Comb Chem High Throughput Screen 16:168-79
Sadikot, Takrima; Swink, Megan; Eskew, Jeffery D et al. (2013) Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol 11:478-88

Showing the most recent 10 out of 11 publications